Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quavonlimab + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MK-1308A is a fixed-dose co-formulation of quavonlimab (MK-1308), an anti-CTLA-4 monoclonal antibody, and pembrolizumab (MK-3475), an anti-PD-1 monoclonal antibody. Developed by Merck & Co., this combination biologic is designed to provide dual checkpoint inhibition, potentially overcoming resistance mechanisms associated with single-agent PD-1 blockade. By simultaneously targeting the CTLA-4 and PD-1 pathways, MK-1308A aims to enhance T-cell activation and proliferation within the tumor microenvironment. It is currently being evaluated in Phase 2 and Phase 3 clinical trials for various malignancies, including hepatocellular carcinoma (often in combination with lenvatinib) and non-small cell lung cancer.
- Other names
- quavonlimab/pembrolizumabpembrolizumab/quavonlimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on quavonlimab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quavonlimab + pembrolizumab.